 Miriam Post
Concepts (361)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stillbirth | 2 | 2024 | 81 | 1.550 |
Why?
| | Ovarian Neoplasms | 16 | 2026 | 595 | 1.500 |
Why?
| | Placenta | 10 | 2024 | 786 | 1.480 |
Why?
| | Cystadenocarcinoma, Serous | 8 | 2026 | 89 | 1.230 |
Why?
| | Uterine Neoplasms | 6 | 2019 | 98 | 1.120 |
Why?
| | Carcinosarcoma | 5 | 2018 | 23 | 1.050 |
Why?
| | Fetal Death | 1 | 2023 | 57 | 0.800 |
Why?
| | Clinical Competence | 3 | 2022 | 1243 | 0.710 |
Why?
| | Pathologists | 3 | 2017 | 19 | 0.710 |
Why?
| | Endometrial Neoplasms | 6 | 2023 | 205 | 0.670 |
Why?
| | Education, Medical, Continuing | 1 | 2022 | 133 | 0.660 |
Why?
| | Tumor Microenvironment | 4 | 2026 | 734 | 0.520 |
Why?
| | Microfilament Proteins | 1 | 2017 | 135 | 0.500 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 14 | 0.440 |
Why?
| | Fetal Growth Retardation | 3 | 2024 | 593 | 0.430 |
Why?
| | Autopsy | 2 | 2024 | 94 | 0.400 |
Why?
| | Immunohistochemistry | 9 | 2026 | 1716 | 0.400 |
Why?
| | Carrier Proteins | 1 | 2017 | 728 | 0.390 |
Why?
| | Lymph Nodes | 4 | 2018 | 503 | 0.390 |
Why?
| | Fetus | 3 | 2024 | 804 | 0.380 |
Why?
| | Pre-Eclampsia | 2 | 2021 | 206 | 0.380 |
Why?
| | Biomarkers, Tumor | 11 | 2026 | 1321 | 0.360 |
Why?
| | Female | 56 | 2026 | 78845 | 0.340 |
Why?
| | Pathology | 3 | 2017 | 21 | 0.340 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 2 | 2026 | 27 | 0.330 |
Why?
| | Pregnancy | 11 | 2024 | 7202 | 0.320 |
Why?
| | Humans | 64 | 2026 | 145475 | 0.310 |
Why?
| | Prognosis | 11 | 2024 | 4316 | 0.300 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 76 | 0.300 |
Why?
| | Osteoblastoma | 1 | 2008 | 2 | 0.290 |
Why?
| | Prolactinoma | 1 | 2008 | 13 | 0.290 |
Why?
| | Breast Neoplasms | 5 | 2026 | 2382 | 0.290 |
Why?
| | Receptors, Estrogen | 6 | 2026 | 401 | 0.280 |
Why?
| | Skull Base | 1 | 2008 | 55 | 0.280 |
Why?
| | Skull Base Neoplasms | 1 | 2008 | 30 | 0.280 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 58 | 0.270 |
Why?
| | Cytomegalovirus | 1 | 2009 | 168 | 0.270 |
Why?
| | Diagnosis, Differential | 6 | 2024 | 1508 | 0.270 |
Why?
| | Lymphatic Vessels | 2 | 2018 | 63 | 0.250 |
Why?
| | Peritoneal Neoplasms | 3 | 2014 | 104 | 0.250 |
Why?
| | Uterus | 3 | 2022 | 227 | 0.250 |
Why?
| | Fetal Diseases | 1 | 2009 | 194 | 0.250 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 206 | 0.250 |
Why?
| | Professionalism | 2 | 2017 | 26 | 0.250 |
Why?
| | Pituitary Neoplasms | 1 | 2008 | 190 | 0.250 |
Why?
| | Interleukin-6 | 3 | 2024 | 776 | 0.250 |
Why?
| | Receptors, Interleukin-8B | 1 | 2026 | 29 | 0.240 |
Why?
| | Ketoglutaric Acids | 1 | 2026 | 22 | 0.240 |
Why?
| | Gestational Age | 4 | 2024 | 987 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2026 | 1149 | 0.230 |
Why?
| | Carnitine | 1 | 2026 | 91 | 0.230 |
Why?
| | Cell Line, Tumor | 12 | 2026 | 3542 | 0.220 |
Why?
| | Infant, Newborn | 4 | 2024 | 6447 | 0.210 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2009 | 440 | 0.210 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 33 | 0.200 |
Why?
| | Chorionic Villi | 1 | 2024 | 25 | 0.200 |
Why?
| | DNA Repair | 1 | 2026 | 254 | 0.200 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2021 | 268 | 0.200 |
Why?
| | Umbilical Arteries | 1 | 2024 | 52 | 0.200 |
Why?
| | Neoplasm Invasiveness | 6 | 2018 | 506 | 0.200 |
Why?
| | Middle Aged | 23 | 2026 | 36215 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1443 | 0.200 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1957 | 0.190 |
Why?
| | Education, Medical, Graduate | 4 | 2017 | 562 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.190 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.190 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 10 | 0.190 |
Why?
| | Fallopian Tubes | 1 | 2022 | 33 | 0.190 |
Why?
| | Histones | 2 | 2026 | 666 | 0.190 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 49 | 0.190 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 325 | 0.190 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2022 | 4 | 0.190 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 641 | 0.180 |
Why?
| | Neoplasm Staging | 5 | 2019 | 1471 | 0.180 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 195 | 0.180 |
Why?
| | Internship and Residency | 3 | 2017 | 1267 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2664 | 0.180 |
Why?
| | Specialty Boards | 1 | 2022 | 42 | 0.180 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 133 | 0.170 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2021 | 9 | 0.170 |
Why?
| | Neoplasm Grading | 4 | 2026 | 310 | 0.170 |
Why?
| | Hysterectomy | 3 | 2022 | 138 | 0.170 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 76 | 0.170 |
Why?
| | Granulosa Cells | 1 | 2021 | 36 | 0.170 |
Why?
| | Cisplatin | 3 | 2026 | 345 | 0.170 |
Why?
| | Premature Birth | 2 | 2024 | 388 | 0.170 |
Why?
| | beta Catenin | 2 | 2023 | 254 | 0.170 |
Why?
| | Antigens, CD | 2 | 2015 | 558 | 0.170 |
Why?
| | Ovarian Follicle | 1 | 2021 | 78 | 0.170 |
Why?
| | Ovary | 1 | 2022 | 233 | 0.160 |
Why?
| | Certification | 1 | 2022 | 119 | 0.160 |
Why?
| | Adult | 23 | 2026 | 40777 | 0.160 |
Why?
| | Decidua | 2 | 2012 | 22 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 265 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 153 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 530 | 0.160 |
Why?
| | Lymphatic Metastasis | 5 | 2026 | 331 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 881 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 192 | 0.150 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 29 | 0.150 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 102 | 0.150 |
Why?
| | Phthalazines | 1 | 2019 | 63 | 0.150 |
Why?
| | Endometrium | 2 | 2022 | 64 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 381 | 0.140 |
Why?
| | Leiomyoma | 1 | 2019 | 61 | 0.140 |
Why?
| | Estrogens | 2 | 2012 | 367 | 0.140 |
Why?
| | Up-Regulation | 1 | 2021 | 847 | 0.140 |
Why?
| | Gene Expression Profiling | 4 | 2019 | 1767 | 0.140 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.140 |
Why?
| | Diverticulum | 1 | 2018 | 15 | 0.140 |
Why?
| | Uterine Diseases | 1 | 2018 | 18 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 2214 | 0.140 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 141 | 0.130 |
Why?
| | Adenocarcinoma | 2 | 2015 | 925 | 0.130 |
Why?
| | Fetal Blood | 2 | 2021 | 327 | 0.130 |
Why?
| | Piperazines | 1 | 2019 | 375 | 0.130 |
Why?
| | Blood Vessels | 1 | 2018 | 167 | 0.120 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2017 | 69 | 0.120 |
Why?
| | Extracellular Matrix | 1 | 2021 | 562 | 0.120 |
Why?
| | B7-H1 Antigen | 3 | 2024 | 244 | 0.120 |
Why?
| | Aged | 14 | 2026 | 26153 | 0.120 |
Why?
| | Receptors, Progesterone | 3 | 2015 | 243 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2015 | 2507 | 0.120 |
Why?
| | Retinopathy of Prematurity | 1 | 2018 | 181 | 0.120 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 33 | 0.120 |
Why?
| | Employment | 1 | 2017 | 184 | 0.110 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 24 | 0.110 |
Why?
| | Keratin-5 | 1 | 2015 | 44 | 0.110 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 52 | 0.110 |
Why?
| | Job Satisfaction | 1 | 2017 | 237 | 0.110 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2015 | 37 | 0.110 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2026 | 423 | 0.110 |
Why?
| | Skin Neoplasms | 2 | 2012 | 849 | 0.110 |
Why?
| | Incidental Findings | 1 | 2015 | 81 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2021 | 874 | 0.110 |
Why?
| | Tuberous Sclerosis | 1 | 2015 | 56 | 0.110 |
Why?
| | Mutation | 2 | 2023 | 4075 | 0.110 |
Why?
| | Mesothelioma, Cystic | 1 | 2014 | 1 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1356 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1217 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 193 | 0.100 |
Why?
| | Chest Pain | 1 | 2015 | 99 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2024 | 534 | 0.100 |
Why?
| | Carcinoma | 1 | 2016 | 225 | 0.100 |
Why?
| | Chorioamnionitis | 1 | 2014 | 50 | 0.100 |
Why?
| | Capillaries | 1 | 2015 | 125 | 0.100 |
Why?
| | Cough | 1 | 2015 | 124 | 0.100 |
Why?
| | Glycoproteins | 1 | 2015 | 354 | 0.100 |
Why?
| | Fertility Preservation | 1 | 2014 | 55 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2019 | 934 | 0.100 |
Why?
| | Accreditation | 1 | 2014 | 101 | 0.100 |
Why?
| | Interleukin-8 | 1 | 2014 | 269 | 0.100 |
Why?
| | Adenomyosis | 1 | 2013 | 7 | 0.100 |
Why?
| | Sarcoma | 1 | 2016 | 207 | 0.100 |
Why?
| | Educational Measurement | 1 | 2016 | 326 | 0.100 |
Why?
| | Survival Rate | 4 | 2018 | 2090 | 0.100 |
Why?
| | Robotics | 1 | 2014 | 90 | 0.100 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2012 | 6 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 250 | 0.090 |
Why?
| | Infertility | 1 | 2013 | 61 | 0.090 |
Why?
| | Luteinizing Hormone | 1 | 2013 | 207 | 0.090 |
Why?
| | Lectins | 1 | 2012 | 44 | 0.090 |
Why?
| | Menstrual Cycle | 1 | 2013 | 145 | 0.090 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 66 | 0.090 |
Why?
| | Fatigue | 1 | 2015 | 364 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2014 | 389 | 0.090 |
Why?
| | Neural Stem Cells | 1 | 2014 | 168 | 0.090 |
Why?
| | Disease Progression | 4 | 2026 | 2864 | 0.090 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 56 | 0.090 |
Why?
| | Mice | 9 | 2026 | 18329 | 0.090 |
Why?
| | Apoptosis | 4 | 2015 | 2440 | 0.090 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 34 | 0.090 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2011 | 19 | 0.090 |
Why?
| | Endometriosis | 1 | 2012 | 58 | 0.090 |
Why?
| | Cicatrix | 1 | 2012 | 69 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 409 | 0.090 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 33 | 0.090 |
Why?
| | Lymph Node Excision | 3 | 2018 | 173 | 0.090 |
Why?
| | DNA Polymerase II | 2 | 2023 | 35 | 0.090 |
Why?
| | Animals | 12 | 2026 | 38030 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2024 | 17291 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 286 | 0.080 |
Why?
| | Paclitaxel | 1 | 2012 | 257 | 0.080 |
Why?
| | Immunocompromised Host | 1 | 2012 | 202 | 0.080 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 23 | 0.080 |
Why?
| | Bridged-Ring Compounds | 1 | 2011 | 31 | 0.080 |
Why?
| | Leptin | 1 | 2012 | 248 | 0.080 |
Why?
| | Trophoblastic Neoplasms | 1 | 2010 | 2 | 0.080 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 17 | 0.080 |
Why?
| | Neoplasms, Squamous Cell | 1 | 2010 | 4 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2012 | 178 | 0.080 |
Why?
| | Taxoids | 1 | 2011 | 114 | 0.080 |
Why?
| | Skin Diseases | 1 | 2012 | 152 | 0.080 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2010 | 36 | 0.080 |
Why?
| | United States | 4 | 2022 | 16098 | 0.080 |
Why?
| | Biological Evolution | 1 | 2014 | 467 | 0.080 |
Why?
| | Cesarean Section | 1 | 2012 | 230 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 279 | 0.080 |
Why?
| | Disease-Free Survival | 2 | 2026 | 767 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 998 | 0.080 |
Why?
| | Biopsy | 3 | 2022 | 1082 | 0.080 |
Why?
| | Tumor Burden | 2 | 2026 | 325 | 0.070 |
Why?
| | Inflammation | 2 | 2018 | 2878 | 0.070 |
Why?
| | Amniocentesis | 1 | 2009 | 20 | 0.070 |
Why?
| | Africa, Eastern | 1 | 2009 | 12 | 0.070 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 99 | 0.070 |
Why?
| | Fever of Unknown Origin | 1 | 2009 | 13 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1193 | 0.070 |
Why?
| | Infarction | 1 | 2008 | 9 | 0.070 |
Why?
| | Cell Survival | 2 | 2026 | 1100 | 0.070 |
Why?
| | Prolactin | 1 | 2008 | 87 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 2008 | 109 | 0.070 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 523 | 0.070 |
Why?
| | Viremia | 1 | 2009 | 160 | 0.070 |
Why?
| | Travel | 1 | 2009 | 136 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 265 | 0.070 |
Why?
| | Headache | 1 | 2008 | 151 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 441 | 0.060 |
Why?
| | Models, Statistical | 1 | 2011 | 671 | 0.060 |
Why?
| | Ultrasonography, Prenatal | 1 | 2009 | 295 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 699 | 0.060 |
Why?
| | Acetyl Coenzyme A | 1 | 2026 | 8 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 222 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2021 | 3623 | 0.060 |
Why?
| | Mixed Function Oxygenases | 1 | 2026 | 43 | 0.060 |
Why?
| | Macrophages | 2 | 2024 | 1507 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 6066 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 686 | 0.060 |
Why?
| | Dioxygenases | 1 | 2026 | 34 | 0.060 |
Why?
| | Homologous Recombination | 1 | 2026 | 37 | 0.060 |
Why?
| | Phenylurea Compounds | 1 | 2026 | 119 | 0.060 |
Why?
| | Survival Analysis | 2 | 2021 | 1374 | 0.060 |
Why?
| | Mice, Nude | 3 | 2012 | 679 | 0.060 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2026 | 76 | 0.060 |
Why?
| | Acetylation | 1 | 2026 | 259 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2009 | 892 | 0.050 |
Why?
| | Cohort Studies | 3 | 2024 | 6013 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8333 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5423 | 0.050 |
Why?
| | BRCA2 Protein | 1 | 2024 | 68 | 0.050 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2024 | 66 | 0.050 |
Why?
| | Prospective Studies | 3 | 2023 | 8057 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2024 | 319 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 53 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2024 | 126 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.050 |
Why?
| | DNA Damage | 1 | 2026 | 437 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 19 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2026 | 465 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 182 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 79 | 0.050 |
Why?
| | Ultrasonography | 2 | 2018 | 785 | 0.040 |
Why?
| | Brain | 1 | 2014 | 2947 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 32 | 0.040 |
Why?
| | Lung | 1 | 2015 | 4106 | 0.040 |
Why?
| | Maternal Age | 1 | 2021 | 128 | 0.040 |
Why?
| | Mice, SCID | 2 | 2012 | 369 | 0.040 |
Why?
| | Cervix Uteri | 1 | 2021 | 50 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1963 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 130 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 665 | 0.040 |
Why?
| | Neutrophils | 1 | 2026 | 1124 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 93 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 820 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 3904 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 756 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 18 | 0.040 |
Why?
| | Estradiol | 2 | 2013 | 515 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 65 | 0.040 |
Why?
| | Young Adult | 4 | 2021 | 14219 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 55 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 156 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 471 | 0.030 |
Why?
| | Pregnancy, Tubal | 1 | 2018 | 5 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.030 |
Why?
| | Ovarian Cysts | 1 | 2018 | 6 | 0.030 |
Why?
| | Fetal Development | 1 | 2021 | 298 | 0.030 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.030 |
Why?
| | Salpingectomy | 1 | 2018 | 15 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 452 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2121 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 194 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2769 | 0.030 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 165 | 0.030 |
Why?
| | Pelvic Pain | 1 | 2018 | 42 | 0.030 |
Why?
| | Abortion, Spontaneous | 1 | 2018 | 118 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1707 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2026 | 11772 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 959 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 730 | 0.030 |
Why?
| | Ifosfamide | 1 | 2016 | 39 | 0.030 |
Why?
| | Risk Factors | 3 | 2018 | 10885 | 0.030 |
Why?
| | Faculty | 1 | 2017 | 147 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | Abortion, Induced | 1 | 2018 | 110 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 49 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2823 | 0.030 |
Why?
| | Risk | 1 | 2018 | 919 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 447 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 319 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 630 | 0.030 |
Why?
| | Time Factors | 1 | 2026 | 7123 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1038 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 148 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 30 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1997 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.030 |
Why?
| | Follicular Phase | 1 | 2013 | 41 | 0.020 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 354 | 0.020 |
Why?
| | Hysteroscopy | 1 | 2013 | 14 | 0.020 |
Why?
| | Luteal Phase | 1 | 2013 | 51 | 0.020 |
Why?
| | Primates | 1 | 2014 | 133 | 0.020 |
Why?
| | Laparoscopy | 1 | 2018 | 481 | 0.020 |
Why?
| | Organ Size | 1 | 2014 | 461 | 0.020 |
Why?
| | Oocytes | 1 | 2014 | 185 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2012 | 2803 | 0.020 |
Why?
| | Cryopreservation | 1 | 2014 | 113 | 0.020 |
Why?
| | Vaginal Neoplasms | 1 | 2012 | 19 | 0.020 |
Why?
| | Karyotyping | 1 | 2012 | 105 | 0.020 |
Why?
| | Anoikis | 1 | 2012 | 31 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1891 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.020 |
Why?
| | Male | 4 | 2017 | 72843 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 848 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2012 | 132 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 191 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 855 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 765 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 178 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 70 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 170 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 146 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2011 | 67 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2012 | 451 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 613 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 34 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 72 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 97 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 200 | 0.020 |
Why?
| | Transfection | 1 | 2012 | 926 | 0.020 |
Why?
| | Organ Specificity | 1 | 2010 | 309 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4295 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 193 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 632 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 1001 | 0.020 |
Why?
| | Adolescent | 1 | 2008 | 22530 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 265 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 749 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 977 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1179 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1041 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 2067 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1808 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5905 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 686 | 0.010 |
Why?
| | Infant | 1 | 2018 | 10077 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2930 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 5216 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|